Auriga Downgrades Myriad Genetics to Hold, Reduces PT to $25

Auriga downgraded its rating on Myriad Genetics MYGN from Buy to Hold. At the same time, Auriga reduced its price target on the company's stock from $27 to $25. In a research report published today, Auriga still maintains a positive view of the company's performance. In the report, Auriga states, "While we continue to like MYGN's steady business mix, emerging product pipeline and support its plans to increase clinical activity, the current valuation pushes us to the sidelines. As such, we are downgrading to Hold (from Buy) and reducing our PT to $25 (from $27)." On Tuesday, Myriad closed at $24.19.